Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
Rhea-AI Summary
Equillium (Nasdaq: EQ) reported fourth-quarter and full-year 2025 results and recent corporate and clinical highlights on March 25, 2026. Key points: no revenue in 2025 versus $41.1M in 2024; FY net loss $22.4M (−$0.39/share); cash and short-term investments $30.3M at Dec 31, 2025; completed a $35M private placement in March 2026 and an up to $50M financing in Aug 2025. Company plans to initiate a Phase 1 proof-of-mechanism study for EQ504 in mid-2026 with data expected ~six months later and expects cash runway into 2029.
AI-generated analysis. Not financial advice.
Positive
- Completed $35M private placement in March 2026 with RA Capital
- Announced August 2025 private financing of up to $50M from healthcare investors
- Cash and short-term investments of $30.3M as of December 31, 2025
- Company expects operating runway into 2029 based on current financing and assumptions
- Planned initiation of Phase 1 proof-of-mechanism study for EQ504 in mid-2026
Negative
- Zero revenue in 2025 versus $41.1M in 2024
- Full-year net loss widened to $22.4M in 2025 from $8.1M in 2024
- R&D spend declined to $12.8M in 2025 from $37.4M in 2024, reflecting wound-down studies
News Market Reaction – EQ
On the day this news was published, EQ declined NaN%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves (e.g., BMEA +0.89%, CRBP -1.96%, ZURA -1.82%), indicating EQ’s pre-news -3.47% move appears more stock-specific than sector-driven.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 13 | Q3 2025 results | Positive | +23.8% | Q3 2025 results plus up to $50M private placement and EQ504 plans. |
| Mar 27 | FY 2024 results | Negative | -35.6% | FY 2024 results with Phase 3 EQUATOR miss on primary endpoint but other benefits. |
| Nov 13 | Q3 2024 results | Positive | -12.3% | Q3 2024 revenue growth, improved net loss, and clinical updates including EQUATOR. |
| Aug 08 | Q2 2024 results | Positive | -1.6% | Q2 2024 profit, higher revenue, and positive data from multiple clinical programs. |
| Jul 18 | Cash update | Positive | -2.0% | Preliminary Q2 2024 cash of $33.3M, boosted by $2.7M Australian tax credit. |
Earnings and financial updates have often produced negative or mixed next-day moves, with several positive updates met by share price declines.
Over the last few earnings and financial updates, Equillium has transitioned from revenue tied to itolizumab and the Ono partnership toward a pipeline- and financing-driven story. Prior releases highlighted growing or stable cash positions ($22.6M–$33.3M), sizeable potential milestone structures, and, more recently, EQ504-focused development and financings. Price reactions to these earnings events have been inconsistent, with both sharp gains and steep selloffs, underscoring that similar fundamental updates have not produced uniform market responses.
Historical Comparison
In the past five earnings-related updates, EQ’s average next-day move was -5.54%, with both strong rallies and steep declines, showing historically volatile reactions around financial disclosures.
Earnings releases have marked a shift from itolizumab- and Ono-linked revenue toward a model centered on EQ504, external financings, and extending cash runway, with oncology and immunology programs evolving alongside capital raises.
Regulatory & Risk Context
Equillium has an effective Form S-3 shelf filed on Nov 13, 2025 to offer up to $250,000,000 in securities, including an at-the-market program of up to $75,000,000 of common stock via LifeSci Capital, providing flexibility to raise capital through equity or other securities over time.
Market Pulse Summary
This announcement detailed Equillium’s 2025 results, highlighting zero revenue versus $41.1M in 2024, sharply lower R&D expenses of $12.8M, a higher net loss of $22.4M, and year-end cash of $30.3M. Together with a new $35M financing, management expects operations funded into 2029. The update reinforced EQ504 as the lead asset, with a Phase 1 study planned for mid-2026 and data roughly six months later, while EQ302 remains under evaluation.
Key Terms
phase 1 medical
proof-of-mechanism medical
ahr medical
ulcerative colitis medical
gi medical
bi-specific inhibitor medical
private placement financial
kol technical
AI-generated analysis. Not financial advice.
Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter
Cash and cash equivalents, inclusive of the March 2026 financing, expected to fund operations into 2029
LA JOLLA, Calif, March 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for its fourth quarter and fiscal year ended December 31, 2025.
“2025 was a transformative year as we sharpened our strategic focus on EQ504 and strengthened our financial position to support its advancement into the clinic,” said Bruce Steel, Chief Executive Officer of Equillium. “Our financing in August 2025 of up to
Recent Corporate & Clinical Highlights:
- In March 2026, announced a private placement financing of
$35 million with RA Capital Management. In August 2025, announced a private placement financing of up to$50 million with a syndicate of leading healthcare investors, including ADAR1 Capital Management, Janus Henderson Investors, Adage Capital Partners LP, Coastlands Capital, and Woodline Partners LP. - Continuing to advance EQ504, a potent and selective AhR modulator with potential for targeted local delivery in GI diseases including UC, as well as inhaled formulations for inflammatory lung diseases. The Company has completed the preclinical work and plans to initiate a Phase 1 proof-of-mechanism study in mid-2026, with data expected approximately six months thereafter.
- Evaluating further advancement of EQ302, its oral, bi-specific inhibitor of IL-15 and IL-21 being developed for GI indications, including celiac disease.
- Hosted a virtual KOL investor event with Dr. Francisco J. Quintana of Harvard Medical School and the late Dr. Brian Feagan of Western Ontario, on Wednesday, November 5, 2025. A replay of the KOL event can be accessed here, and key takeaways include:
- AhR modulation is i) a differentiated and multi-modal approach to decreasing tissue inflammation while promoting tissue repair; and ii) clinically validated in skin and GI diseases, through VTAMA® and the botanical indigo naturalis, respectively.
- EQ504 i) is a potent and selective AhR modulator that may be administered orally and is formulated to target the colon, representing a next-generation therapeutic to treat UC locally; and ii) has broad therapeutic potential in UC as a potential standalone oral therapy, or in combination with other therapeutic approaches.
- AhR modulation is i) a differentiated and multi-modal approach to decreasing tissue inflammation while promoting tissue repair; and ii) clinically validated in skin and GI diseases, through VTAMA® and the botanical indigo naturalis, respectively.
Fourth Quarter and Full Year 2025 Financial Results
Revenue for the fourth quarter of 2025 was
Research and development (R&D) expenses for the fourth quarter of 2025 were
General and administrative (G&A) expenses for the fourth quarter of 2025 were
Net loss for the fourth quarter of 2025 was
Cash, cash equivalents and short-term investments totaled
About EQ504
EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal, non-immunosuppressive mechanism of action designed to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. EQ504’s preclinical properties provide the potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and product platform targeting immuno-inflammatory pathways.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future”, “potential” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements include, but are not limited to, statements regarding Equillium’s expectation that the cash and cash equivalents on its balance sheet as of December 31, 2025, together with the recently completed financing of
Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
| Equillium, Inc. | |||||||
| Condensed Consolidated Balance Sheets | |||||||
| (In thousands) | |||||||
| (unaudited) | |||||||
| December 31, | December 31, | ||||||
| 2025 | 2024 | ||||||
| Assets | |||||||
| Cash, cash equivalents and short-term investments | $ | 30,277 | $ | 22,575 | |||
| Prepaid expenses and other assets | 952 | 2,665 | |||||
| Operating lease right-of-use assets | 658 | 364 | |||||
| Total assets | $ | 31,887 | $ | 25,604 | |||
| Current liabilities | |||||||
| Accounts payable and other current liabilities | $ | 2,934 | $ | 6,356 | |||
| Total current liabilities | 2,934 | 6,356 | |||||
| Long-term operating lease liabilities | 356 | 187 | |||||
| Total liabilities | 3,290 | 6,543 | |||||
| Total stockholders' equity | 28,597 | 19,061 | |||||
| Total liabilities and stockholders' equity | $ | 31,887 | $ | 25,604 | |||
| Equillium, Inc. | |||||||||||||||||
| Condensed Consolidated Statements of Operations | |||||||||||||||||
| (In thousands, except share and per share data) | |||||||||||||||||
| (unaudited) | |||||||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||
| Revenue | $ | - | $ | 4,392 | $ | - | $ | 41,095 | |||||||||
| Operating expenses: | |||||||||||||||||
| Research and development | 1,536 | 7,314 | 12,843 | 37,428 | |||||||||||||
| General and administrative | 2,426 | 1,775 | 10,791 | 11,936 | |||||||||||||
| Total operating expenses | 3,962 | 9,089 | 23,634 | 49,364 | |||||||||||||
| Loss from operations | (3,962 | ) | (4,697 | ) | (23,634 | ) | (8,269 | ) | |||||||||
| Total other income (expense), net | 187 | (734 | ) | 1,236 | 563 | ||||||||||||
| Loss before income tax expense | (3,775 | ) | (5,431 | ) | (22,398 | ) | (7,706 | ) | |||||||||
| Income tax expense | - | 361 | - | 361 | |||||||||||||
| Net loss | $ | (3,775 | ) | $ | (5,792 | ) | $ | (22,398 | ) | $ | (8,067 | ) | |||||
| Net loss per share, basic and diluted | $ | (0.04 | ) | $ | (0.16 | ) | $ | (0.39 | ) | $ | (0.23 | ) | |||||
| Weighted-average number of common shares outstanding, basic and diluted | 91,881,058 | 35,457,559 | 57,304,181 | 35,357,641 | |||||||||||||
